Chemical carcinogens often induce neoplasms which differ qualitatively and quantitatively from tumors that occur spontaneously i n the tissue of interest.
INTRODUCTION
My topic implies that I can identify for you a set of tumors which do not occur spontaneously, but only after some toxic exposure. There are some circumstances which encourage this approach, for example, the hepatic hemangiosarcomas in older male humans after exposure to vinyl chloride, or a 75% prevalence of anaplastic oligodendrogliomas of subpial spinal cord in young rats exposed to methylnitrosurea. Similarly, a high incidence of carcinomas or hemangiosarcomas of the nose in rodents should implicate an aerosolized toxin. The problem with the profile approach to induced tumors is that it breaks down as often as it works. For it to be useful implies that there is some essential difference between induced tumors and spontaneous ones.
If we review the NCI and NTP bioassays, now numbering some 250, involving about 100,000 rats and mice in 2-year studies, we find that the liver is the organ which most commonly has neoplastia in the positive bioassays; about 20% of the positives are in liver only. The lung and mammary gland are other' frequent target organs. These organs are also commonly neoplastic in untreated animals. So how does one identify the "profile" of the induced tumors as distinct from the spontaneous ones?
Profiles of induced tumors require at least two major considerations: the ability to dis-BUCCI TOXICOLOGIC PATHOLOGY tinguish "induced" tumors from "spontaneous" ones, and the ability to identify systematic characteristics in the induced ones which differ from those present in the spontaneous ones. In this report, spontaneous tumors are those which occur without known exposure to carcinogens; as a first approximation, induced tumors are those which occur after exposure and which differ in some way from those expected in unexposed animals. The terms tumor and neoplasm are used interchangeably to designate either benign or malignant growths. For scientists to be able to distinguish unequivocally between spontaneous and induced tumors would have great practical importance in basic carcinogenesis research as well as in carcinogenesis bioassays. In the bioassay situation, a systematized catalog of distinguishing characteristics of induced tumors could be used to decide that an animal had been exposed to a carcinogen when specific tumor characteristics were present; this could resolve the present uncertainty about the outcome of nearly half the bioassays sponsored by NCI/NTP. The topic of bioassays is developed further by Hottendorf else-Lvhere in this symposium.
In order to consider a profile, or systematized catalog of induced neoplasms, they must be distinguishable from spontaneous ones so they may be characterized. Thus one obvious starting point would be to examine tumors that occur in treated animals for charact e r i s t i cs which cons is ten t 1 y differentia t e them from those occurring in controls. The first characteristic is incidence.
The control incidence becomes the "expected" and those occurring in the treated animals are the "observed." When the observed exceed the expected we can call those induced and begin to examine them for some unique pattern of characteristics which we could apply later.
But the plan soon runs into trouble. The control incidence is not dependable. Dr. Hardisty earlier in this symposium and as well as others (2, 3, 5, 9) have indicated some of the documentation of the variability of tumor rates in untreated rodents. As you know, the age, sex, diet, and strain are major sources of variation. Interlaboratory (interpathologist?) differences as well as variations over time in the same laboratory are also common (10).
It is against this kind of highly variable background that we seek identifiable differ-ences between these so-called spontaneous tumors and others that might result from our treatment. In this presentation, I hope to persuade you that 1) there is probably no essential difference between induced and spontaneous tumors, yet 2) in the context of well-defined experiments, induced tumors can often be detected with confidence.
As a practical matter, we know that if the compound being tested is a carcinogen, an increased number of tumors will occur in the treated animals. The tumors may occur sooner than spontaneous ones, be more agressive, or be more numerous per animal. Tumor types not present in the control may be induced, i.e., rare for the organ. Alternatively, a muItiplicity of common types of tumor may occur in various organs. A particularly troublesome pattern is that in which a rare tumor occurs infrequently in a partiicular organ, in a way that the number of neoplasms is not increased statistically. The pathologist bears a particular burden to recognize the unexpected under all circumstances.
The induced tumors vary in parallel with spontaneous ones as a function of age, sex, strain, laboratory, dose, and route of administration of the agent, etc. The response is perhaps a little less sensitive to variation than spontaneous incidences, but tumor yields still vary remarkably even in some repetitions with seemingly identical conditions.
To reiterate, induced tumors can differ from spontaneous tumors, but only to the extent that spontaneous tumors can be characterized. There is probably no single marker or group of markers that will unequivocally identify the class of induced tumors as distinct from spontaneous ones. The pathologist must accept the responsibility to know what to expect statistically as spontaneous, and to be alert for observed incidences which differ.
At a practical level we can tabulate historic incidences of tumors in untreated animals, and establish broad average rates for each age, species, strain, sex, and site. We will have concurrent control animals in our experiments, and we will continue to accumulate data to establish and further refine our "expected" findings. Against those, any large deviation in the "observed" outcome will be suspect. Even isolated individual cases of unusual occurrences could be suspect, but there is very little we can measure about that individual case to give us confidence that it was induced. So far, we don't have "Koch's Pos-tulates" for neoplasia. This is not to say that experimental systems have no reproducible characteristics. But the characteristics are inconsistent among the systems.
For example, Becker (1) reports the production of hepatic neoplasms in three strains of mice exposed to four different initiation regimens plus phenobarbital; he believes he can distinguish the induced hepatocarcinomas from the genetically conditioned spontaneous neoplasms by their increased cellular atypism and the higher degree of dysmorphism of trabeculi produced. But there is overlap. He reports also that phenobarbital as a promotor increased the number of "spontaneous" tumors.
Stinson and others (7) showed that nitrofen-induced hepatocarcinomas in B6C3F1 mice had larger cells than hepatocarcinomas of untreated mice, and that the induced foci and carcinomas were acidophilic while the spontaneous ones were basophilic.
Lipsky et a1 (4) used safrole to induce hepatocarcinomas in BALB/c mice. He produced a variety of foci, including eosinophilic, basophilic, and clear cell. Some foci progressed through adenomas to carcinoma. Only one basophilic focus was found in untreated mice. In these examples, the investigators were able to discern induced from spontaneous tumors.
In contrast, Stoner and others (8) used three dose levels of six different carcinogens to compare intraperitoneal administration with oral administration for effect on lung tumor production in A/J mice. The tumors produced did not differ from spontaneous ones in any morphologic way. (The spontaneous rate was 25-30%.) They did differ in number per mouse and in incidence; males and females responded similarly. The six-by-three design in two sexes and two routes provided a complex matrix and the responses varied as a function of route and dose, but not linearly with dose, and all compounds were not effective. My point is simply that an individual tumor could not be distinguished as either induced or spontaneous.
i"at emerges is that effective carcinogens can produce large showers of -tumors. Under controlled conditions these can be detected easily, although not necessarily because of any unique cellular or morphologic characteristics. It is their number and the temporal relationship to exposure which are most revealing. And even though we can distinguish induced tumors in certain experiments, we really can learn very little from them that we can use to generalize and apply to other cases.
Any bona fidc distinction between induced and spontaneous tumors would require demonstration at the molecular level of some essential difference; I submit that there isn't one and that the differential characteristics which I've been talking about until now are only incidental attributes of the exposure conditions. When we understand carcinogenesis completely I believe we will know that the apparent difference between them is probably only temporal; the induction events for the spontaneous tumors are merely unrecognized.
Nevertheless, if we have good records about the characteristics of spontaneous t_umors and we control our experiments well, we can often know when tumors result from our interventions. However, the knowledge is empirical and not related to unique mechanisms of causation.
If I may rephrase and juxtapose some of the things we heard this morning from Drs. Farber and Vesselinovich, we can frame a simplistic hypothesis for the origin of neoplasia, and see whether it fits our experience.
We can accept that exogenous carcinogens must usually be activated to ultimate proximal carcinogens and that activation systems (epoxidation, alkylation, etc.) are variably distributed among cells in time and location. Thus the liklihood of being exposed to a carcinogen varies greatly, In like manner, deactivation systems exist that vary qualitatively and quantitatively, and these may even. be enhanced by preceding or concurrent exposure to other xenobiotics. We can accept that DNA is the ultimate target molecule for most initiation events (molecular lesions). These events occur in all cells, whether deliberately exposed (induced) or through normal life processes (diet and hormones).
Several model systems propose that susceptibility to initiation is cell-cycle dependent, and that cells in S phase or early G, are most vulnerable, This correlates with our experience that tumors are far more abundant in proliferating tissues. It explains why embryos are resistant to tumor induction before organogenesis, and why breast cancer did not increase in Japanese females exposed to radiation before age 9, i.e., neither have proliferating stem cells. But once those proliferating BUCCI TOXICOLOGIC PATHOLOGY cell populations are present, the organs are uniquely susceptible. Those of us preoccupied with rodents don't usually appreciate that 85 or 90% of human malignancies are in epithelia, systems that normally have considerable proliferative activity. My guess is that rodents must retain a higher proportion of mesenchymal cell turnover than humans do, to have the sarcoma rates that we see in them. To keep the system complex, we must remember that the DNA lesions can be repaired differentially, too. If cells in S and GI are favored targets, and if one round of proliferation is required to "fix" the initiating molecular lesion, and if proliferation is required again after promotion, then proliferating tissues are where the action is; thus, whatever age, sex, organ system, and other concomittant conditions tend toward cell proliferation, these should predispose toward neoplasia and should be reflected in our incidence statistics. If all normal cells contain repressed cellular oncogenes and if derepression occurs by injury to DNA or some other molecule, or by hormone regulatory aberration, the gene products can stimulate transformation and proliferation. We can guess that there will be a cascade of agonists and antagonists at this stage, too.
The very term oncogene may turn out to be a misnomer, derived from viral oncology. I'd like to believe those are normal genes that stimulate cell proliferation under some other (fetal?) circumstances.
The gene products probably specify a number of cell attributes which predispose the cell to survive in the new chemical environment. Some attributes will indirectly affect antigenic markers (carcinoembryonic antigen), enzyme increases and decreases (y-glutamyltransferase), or other biochemical characteristics of the cell (a-fetoprotein). We have been preoccupied with these incidental attributes in recent years, trying to make them the essence of premalignancy. These attributes will probably include the factors that effect cell transformation and which control its differentiation and its ultimate escape from normal regulation. Again there are opposing actions; we know that induced cell proliferations can be arrested and even reversed.
Finally, it's becoming clearer that the initial cellular events are relatively few in num-ber and potentially ubiquitious; all cells may, well experience initiating "hits." The subsequent fixation of the initiating event, and continuing support of promotional events, are highly probablistic, statistical results of a myriad of off-setting interactions, ultimately to affect regulation of cell proliferation and differentiation. This is not news in itself; the news is that the evidence is firmer.
If we have trouble deciding what tumor induction means, or what a carcinogen is, we should consider all the studies of the effects of dietary lipid on neoplasia, and think about mechanism. And we should recall the observation that transplantation of presomite embryos can cause teratocarcinoma (6) and think about "induction" and "carcinogen." We very soon are forced to think about regulation of cell proliferation in terms of endogenous and cell to cell regulatory mechanisms independent of bizarre xenobiotics.
An oversimplification is to believe that cells have a protective mechanism to invoke when they are threatened with a potentially catastrophic event like an aberration in their genetic material (e.g., an "initiating hit"). Those abberyations are inevitable in all phylogeny. Once the mechanism is invoked, it can be modulated by opposing regulatory cascades like those that modulate all other cellular events, The outcome (tumor or not) would be mostly a function of the modulation processes. It would be the modulation processes which therefore determine the spontaneous tumor rates. When we come in with our strange nonpolar xenobiotics, we supply a superabundance of damage to DNA and also overwhelm the modulatory drives and sustain them in the direction of neoplasia-that's my current view of induced ' tumors. We cannot usually recognize one by examining it in isolation, because it is not intrinsically unique.
